Cincor Pharma, Inc.
SEC CIK 1868734 · CINC · last insider filing 2023-02-28
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Healy James | Director | filed 2022 - 2023 |
| Thero John F | Director | filed 2022 - 2023 |
| Ignelzi Troy A. | Director | filed 2022 - 2023 |
| Lee June | Director | filed 2022 - 2023 |
| Allison David D. | Director | filed 2022 - 2023 |
| de Garidel Marc | Director · Chief Executive Officer | filed 2022 - 2023 |
| Pitts Jason | Director | filed 2022 - 2022 |
| Bhaman Maina | Director | filed 2022 - 2022 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Freeman Mason | EVP Clinical Development | filed 2022 - 2023 |
| Kalb Michael Wayne | EVP & Chief Financial Officer | filed 2022 - 2023 |
| Pearce Catherine | Chief Operating Officer | filed 2022 - 2023 |
| Coelho Mary Theresa | EVP CFO & Chief BD Officer | filed 2022 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.